[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 144
1. Keck T, Hopt UT: [Total pancreatectomy: renaissance of a surgical procedure]. Chirurg; 2008 Dec;79(12):1134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the indication for oncologic total pancreatectomy, rescue pancreatectomy, and removal of the whole pancreas for chronic pancreatitis.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Humans. Image Processing, Computer-Assisted. Neoplasm Staging. Neuroectodermal Tumors, Primitive / mortality. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / surgery. Pancreatitis, Chronic / mortality. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / surgery. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2003 Jul 15;76(1):92-8 [12865792.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315 [14662530.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3566-72 [8855802.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):295-8 [7524375.001]
  • [Cites] Dig Liver Dis. 2006 Jun;38(6):415-9 [16527551.001]
  • [Cites] Ann Intern Med. 1975 Dec;83(6):778-81 [1200523.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):61-70 [16794390.001]
  • [Cites] Pancreatology. 2001;1(5):477-85 [12120228.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1191-204; discussion 1204-6 [16332474.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] Surgery. 2007 Oct;142(4):572-8; discussion 578-80 [17950350.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):490-500 [18376195.001]
  • [Cites] Am Surg. 2008 Jun;74(6):530-6; discussion 536-7 [18556996.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):489-97 [8103251.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Pancreas. 1987;2(2):170-5 [2819857.001]
  • [Cites] Dig Surg. 2006;23(4):229-34 [16943670.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):651-6 [18085343.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):37-44 [18607267.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):131-40 [1867520.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):913-24 [7660254.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Zentralbl Chir. 2007 Feb;132(1):26-31 [17304432.001]
  • [Cites] Surgery. 2005 Oct;138(4):618-28; discussion 628-30 [16269290.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Ann Surg. 1978 Sep;188(3):317-22 [686897.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Diabet Med. 1997 Feb;14 (2):99-110 [9047086.001]
  • [Cites] N Engl J Med. 1966 Mar 17;274(11):599-602 [5930007.001]
  • [Cites] Surgery. 1993 Dec;114(6):1196-204; discussion 1205-6 [8256226.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Arch Surg. 2007 Apr;142(4):347-54 [17438169.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):183-8 [18392712.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):44-7; discussion 48 [11146775.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):591-8 [15798460.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] Med Clin North Am. 2000 May;84(3):707-18 [10872427.001]
  • [Cites] Ann Surg. 1991 Nov;214(5):575-80 [1953110.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):559-67; discussion 568-9 [15051008.001]
  • [Cites] Ann Surg. 1966 Nov;164(5):830-4 [5923106.001]
  • [Cites] World J Surg. 2001 Apr;25(4):452-60 [11344398.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):138-43 [8439212.001]
  • [Cites] World J Surg. 1996 Mar-Apr;20(3):288-93; discussion 294 [8661833.001]
  • [Cites] Transplant Proc. 1977 Mar;9(1):233-6 [405770.001]
  • (PMID = 18998103.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Watanabe Y, Horiuchi A, Sato K, Yukumi S, Sugishita H, Yoshida M, Doi T, Yamamoto Y, Ishida N, Kameoka K, Kawachi K: Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case. Surg Today; 2010 May;40(5):465-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case.
  • A 61-year-old man with an intraductal papillary mucinous neoplasm (IPMN) and carcinoma in situ (CIS) of the pancreatic body initially underwent a distal pancreatectomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma in Situ / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):576-89 [7726368.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 1999 Feb;177(2):117-20 [10204552.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Surg Today. 2008;38(4):371-6 [18368332.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • (PMID = 20425552.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Søreide K, Immervoll H, Molven A: [Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen; 2006 Mar 23;126(7):905-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic adenocarcinoma is a relatively frequent cancer with an extremely poor prognosis.
  • Until recently, the natural history of pancreatic adenocarcinoma has not been possible to study, but the identification of precursor lesions (pancreatic intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive adenocarcinoma.
  • MATERIAL AND METHODS: Relevant literature from the period of 1996-2005 was found by searching the Medline database, combining the terms "pancreas", "cancer", "PanIN" and "neoplasia".
  • RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to pancreatic adenocarcinoma.
  • PanIN grade I to III represent stepwise morphological alterations in the pancreatic ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554881.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


Advertisement
4. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Tanaka M: Important clues to the diagnosis of pancreatic cancer. Rocz Akad Med Bialymst; 2005;50:69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important clues to the diagnosis of pancreatic cancer.
  • Widespread awareness of important clues to the diagnosis is particularly important to improve the prognosis.
  • Dilatation of the main pancreatic duct on ultrasonograms and/or CT scans, hyperamylasemia incidentally found during routine blood examinations, and recent onset diabetes mellitus must lead to thorough imaging studies of the pancreas.
  • Of particular interest is the fact that two of the 9 patients had carcinoma in situ that could be diagnosed only by cytology of the pancreatic juice.
  • IPMN may be the only clue to the early diagnosis of pancreatic carcinoma presenting with no clinical symptoms or abnormalities on imaging studies.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358942.001).
  • [Journal-full-title] Roczniki Akademii Medycznej w Białymstoku (1995)
  • [ISO-abbreviation] Rocz. Akad. Med. Bialymst.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


6. Nanashima A, Kinoshita N, Nakanuma Y, Zen Y, Sumida Y, Abo T, Hidaka S, Takeshita H, Yasutake T, Hayashi T, Nagayasu T: Clinicopathological features of "intraductal papillary neoplasm of the bile duct" and patient outcome after surgical resection. Hepatogastroenterology; 2008 Jul-Aug;55(85):1167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Intraductal papillary neoplasm of the bile duct (IPNB) represents a biliary papillary tumor mainly growing in the bile duct lumen resembling intraductal papillary mucin-producing neoplasm of the pancreas.
  • Tumor markers were not valuable for diagnosis.
  • Five cases were well-differentiated adenocarcinoma and 1 had poorly differentiated adenocarcinoma.
  • In-situ spread of carcinoma was seen along biliary mucosa in 3 cases.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795651.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Albores-Saavedra J, Weimersheimer-Sandoval M, Chable-Montero F, Montante-Montes de Oca D, Hruban RH, Henson DE: The foamy variant of pancreatic intraepithelial neoplasia. Ann Diagn Pathol; 2008 Aug;12(4):252-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Foamy gland adenocarcinoma is a variant of pancreatic ductal carcinoma, whose precursor has not been described.
  • We describe here the morphologic and immunohistochemical features of the pancreatic intraepithelial neoplasia (PanIN) lesions associated with invasive foamy pancreatic adenocarcinoma.
  • The PanIN-1 lesions were found in the nonneoplastic pancreas and were similar to the PanIN-1 lesions of ordinary pancreatic ductal carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology


8. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M: Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol; 2008 Aug;21(8):1044-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas.
  • Desmoplasia is a common feature of infiltrating ductal adenocarcinoma of the pancreas.
  • To investigate the characteristics of periostin immunodeposition in pancreatic ductal neoplasms, we performed immunohistochemistry and in situ hybridization, focusing on tumor-stromal cells interactions.
  • Eighty-one surgically resected pancreatic lesions, including 35 pancreatic ductal adenocarcinoma, 26 intraductal papillary-mucinous neoplasms, 11 mucinous cystic neoplasms and 9 chronic pancreatitis, were studied.
  • Periostin gene expression was detected solely in the stromal cells on in situ hybridization.
  • Intraductal papillary-mucinous neoplasms were classified into four groups on the basis of the histological grade, namely, adenoma, non-invasive adenocarcinoma, adenocarcinoma with microscopical invasion and with macroscopically evident invasion.
  • In intraductal papillary-mucinous neoplasm, periostin deposition in the periductal stroma increased in frequency and intensity in adenocarcinoma compared with adenomas (P=0.014).
  • This is the first report to describe the periostin immunohistochemistry in intraductal papillary mucinous neoplasm of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cell Adhesion Molecules / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Pancreatic Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Pancreatitis, Chronic / metabolism. Pancreatitis, Chronic / pathology. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487994.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DNA, Neoplasm; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


10. Pilleul F, Rochette A, Partensky C, Scoazec JY, Bernard P, Valette PJ: Preoperative evaluation of intraductal papillary mucinous tumors performed by pancreatic magnetic resonance imaging and correlated with surgical and histopathologic findings. J Magn Reson Imaging; 2005 Mar;21(3):237-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At histologic analysis, three cases were classified as benign, three as borderline tumors, and 18 as carcinomas (eight in situ, 10 invasive).
  • Excellent agreement was found between the interpreters (0.90) in the evaluation of ductal involvement, good in the evaluation of lesion location (0.80) and in the diagnosis of malignant transformation (0.74).
  • The correlation between MRI and histopathologic results was excellent in the evaluation of ductal involvement (0.90, sensitivity = 100%, specificity = 94%) and moderate in the evaluation of lesion location (0.57, sensitivity = 87%, specificity = 56%) and in the diagnosis of malignant transformation (0.60, sensitivity = 83%, specificity = 83%).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Magnetic Resonance Imaging / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15723374.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Huo Z, Yang D, Chang XY, Wan JW, Chen J: [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases].
  • OBJECTIVE: To study the clinicopathologic features and diagnosis of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • It affected patients in older age group (mean age = 59) and was located mainly in the head of pancreas (60%).
  • Features of in-situ or invasive malignancy were present in 15 of the 19 cases (78%).
  • The prognosis after surgical resection however is better than that of conventional pancreatic adenocarcinoma.
  • Early recognition by radiologic examination (including ERCP) and pancreatic cytology would be helpful in early diagnosis.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Cell Cycle Proteins / analysis. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pancreatectomy. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Prognosis. Receptor, ErbB-2 / analysis. Treatment Outcome


12. Osvaldt AB, Wendt LR, Bersch VP, Backes AN, de Cássia A Schumacher R, Edelweiss MI, Rohde L: Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice. Surgery; 2006 Nov;140(5):803-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice.
  • BACKGROUND: Pancreatic ductal adenocarcinoma has a poor long-term prognosis.
  • METHODS: Ninety male, Mus musculus, CF-1 mice underwent a median laparotomy and 1 mg of DMBA was implanted into the proximal pancreas held in place by a purse-string suture.
  • The specimens were evaluated blind by 2 pathologists for the presence of the following histology: normal ducts, reactive hyperplasia, PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3, and adenocarcinoma.
  • All pancreata with adenocarcinoma had concomitant PanIN lesions.
  • CONCLUSIONS: The DMBA experimental model in mice induces PanIN lesions and ductal adenocarcinoma that have similar histology to that of human pancreatic cancer.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene. Carcinoma in Situ / chemically induced. Carcinoma, Pancreatic Ductal / chemically induced. Disease Models, Animal. Pancreatic Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084724.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


13. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB: Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer; 2006 Jun 25;108(3):163-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall.
  • These cytologic features were subsequently correlated with the histologic diagnosis.
  • Necrosis distinguished IPMN with carcinoma from IPMN-adenomas and IPMN with moderate dysplasia (P < .00001), and was more often observed with invasion than IPMN-carcinoma in situ (P < .05).
  • Pale nuclei with parachromatin clearing was found to be a nuclear feature that was suspicious for at least carcinoma in situ (P < .001).
  • In addition, significant background inflammation (neutrophils and histiocytes) was found to be more characteristic of IPMN with at least carcinoma in situ (P = .002).
  • The presence of tight epithelial cell clusters is consistent with a neoplasm of at least moderate dysplasia, and abundant background inflammation and parachromatin clearing correlated with the presence of at least carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550572.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


14. Takahashi H, Nakamori S, Nakahira S, Tsujie M, Takahshi Y, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. Ann Surg Oncol; 2006 Jul;13(7):955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • RESULTS: Of the 20 patients, 13 had benign IPMNs, including adenomas (n = 10) and borderlines (n = 3), and 7 had malignant IPMNs, including carcinomas in situ (n = 4) and minimally invasive IPMNs (n = 3).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Matos JM, Schmidt CM, Thomas HJ, Cummings OW, Wiebke EA, Madura JA, Patrick LJ Sr, Crowell PL: A pilot study of perillyl alcohol in pancreatic cancer. J Surg Res; 2008 Jun 15;147(2):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Apoptosis was quantified with ApopTag in situ, Bak staining, and light microscopy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Monoterpenes / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / metabolism. Female. Humans. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pilot Projects. Treatment Outcome. bcl-2 Homologous Antagonist-Killer Protein / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498869.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-19-9 Antigen; 0 / Monoterpenes; 0 / bcl-2 Homologous Antagonist-Killer Protein; 319R5C7293 / perilla alcohol
  •  go-up   go-down


16. Koorstra JB, Feldmann G, Habbe N, Maitra A: Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg; 2008 Jul;393(4):561-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pancreatic ductal adenocarcinoma (i.e., pancreatic cancer) is an almost universally lethal disease.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):6-13 [12573429.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):133-40 [12631453.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Arch Dermatol. 2003 Aug;139(8):1019-25 [12925390.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:15 [12605716.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):651-7 [15277238.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Bull Osaka Med Coll. 1990 Nov;36(1-2):1-11 [2135640.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5087-9 [8221640.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1708-11 [8194721.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11544-8 [8524800.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Development. 1996 Mar;122(3):983-95 [8631275.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5360-4 [8968085.001]
  • [Cites] J Pathol. 1996 Oct;180(2):160-5 [8976874.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1634-7 [9134998.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):363-9 [9663429.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):89-93 [15626591.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2485-90 [15861417.001]
  • [Cites] Mol Cancer Res. 2005 Jul;3(7):413-23 [16046552.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101 [16169155.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 [16449183.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):155-62 [17297654.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • [Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S61-70 [17486053.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Mini Rev Med Chem. 2007 Jun;7(6):599-608 [17584158.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R88-95 [17613553.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):238-44 [18157091.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2495-504 [10861425.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):266-73 [11561603.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12683-8 [11675499.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8830-7 [11751405.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1361-9 [11943721.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):544-8 [11956906.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Trends Mol Med. 2002 Jun;8(6):288-93 [12067615.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4301-6 [12082617.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Harvey Lect. 2000-2001;96:73-92 [12200872.001]
  • (PMID = 18283486.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113669-02; United States / NCI NIH HHS / CA / R01 CA113669-01; United States / NCI NIH HHS / CA / CA113669-02; United States / NCI NIH HHS / CA / CA113669-04; United States / NCI NIH HHS / CA / CA113669-03; United States / NCI NIH HHS / CA / R01 CA113669-05; United States / NCI NIH HHS / CA / R01 CA113669-03; United States / NCI NIH HHS / CA / R01 CA113669; United States / NCI NIH HHS / CA / R01 CA113669-04; United States / NCI NIH HHS / CA / CA113669-05; United States / NCI NIH HHS / CA / CA113669-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Gastric Mucins; 0 / KRAS protein, human; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / apomucin; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 104
  • [Other-IDs] NLM/ NIHMS98193; NLM/ PMC2666329
  •  go-up   go-down


17. Mansour JC, Schwartz L, Pandit-Taskar N, D'Angelica M, Fong Y, Larson SM, Brennan MF, Allen PJ: The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg; 2006 Dec;10(10):1354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
  • Previous studies have suggested that whole body positron-emission tomography (PET) can distinguish between benign and malignant cysts of the pancreas.
  • Patients were identified (n = 68) who had undergone whole body PET imaging for a cystic lesion of the pancreas between Jan.
  • Within the resected group of patients (n=21), four of the seven patients (57%) with either in situ or invasive malignancy (adenocarcinoma: 3 of 5, papillary mucinous carcinoma: 1 of 2) had positive PET imaging (mean SUV, 5.9; range 2.5-8.0), and 2 of the 14 patients (14%) with benign lesions had positive PET imaging (serous cystadenoma, n=1, SUV=3.3; pseudocyst n=1, SUV=2.7).
  • We do not believe whole body FDG-PET to be essential in the evaluation of cystic lesions of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma, Mucinous / diagnostic imaging. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Surgery. 2005 Oct;138(4):672-9; discussion 679-80 [16269296.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Jun;3(6):461-3 [16167022.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):56-61 [9627172.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):970-7 [14675706.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):675-80 [11685032.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Surgery. 2002 Oct;132(4):628-33; discussion 633-4 [12407346.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):1007-9; discussion 1009 [16530543.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Cancer Treat Rev. 2005 Nov;31(7):507-35 [16257126.001]
  • (PMID = 17175454.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Rautou PE, Lévy P, Vullierme MP, O'Toole D, Couvelard A, Cazals-Hatem D, Palazzo L, Aubert A, Sauvanet A, Hammel P, Hentic O, Rebours V, Pelletier AL, Maire F, Ruszniewski P: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol; 2008 Jul;6(7):807-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study.
  • BACKGROUND & AIMS: Because there is a low risk of malignancy for intraductal papillary and mucinous neoplasms of the pancreas (IPMNs) confined to branch ducts (BD), patient follow-up evaluation without surgery is possible.
  • Surgery, performed in 8 of 12 patients, found 4 IPMN-adenomas, 1 borderline-IPMN, and 4 IPMN carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2008 Jul;6(7):724-5 [18602034.001]
  • (PMID = 18304885.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


20. Genevay M, Dumonceau JM, Pepey B, Pache JC, Rubbia-Brandt L, McKee TA: Fluorescence in situ hybridization as a tool to characterize genetic alterations in pancreatic adenocarcinoma. Pancreas; 2010 May;39(4):543-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization as a tool to characterize genetic alterations in pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418759.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


21. Katabi N, Klimstra DS: Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol; 2008 Dec;61(12):1303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach.
  • In addition, IPMNs sometimes can be confused with other primary cystic lesions of the pancreas.
  • As a result, the correct diagnosis of IPMN can be challenging.
  • This review addresses the clinical and pathological features of IPMNs, emphasising their diagnostic criteria, differential diagnosis and biological behaviour.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma in Situ / diagnosis. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Pancreatectomy. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703569.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 73
  •  go-up   go-down


22. Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH: [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):102-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expressions of TOP2A and HER2/neu proteins were detected by using immunohistochemistry, while gene amplifications of TOP2A and HER2/neu were assessed by using multi-color fluorescence in situ hybridization (FISH).
  • All the samples were of paraffin embedded and 10% formalin fixed tissue, including 26 cases of pancreatic ductal adenocarcinomas with adjacent non-neoplastic pancreatic tissues, 10 cases of chronic panreatitis, and 10 cases of normal pancreas.
  • By FISH, 9/10 TOP2A amplified adenocarcinomas showed TOP2A and HER2/neu gene coamplification, while one case with HER2/neu gene amplification adenocarcinoma showed no TOP2A amplification.
  • No expression of TOP2A, HER2/neu proteins and no amplification of TOP2A and HER2/neu gene were detected in adjacent non-neoplastic pancreatic tissues, chronic pancreatitis tissues and normal pancreas.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / metabolism. Carcinoma, Pancreatic Ductal / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Genes, erbB-2. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493384.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


23. Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM: HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Dig Dis Sci; 2008 Nov;53(11):3026-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.
  • We studied HER2 gene amplification, HER2 copy numbers, and chromosome 17 copy numbers using fluorescence in situ hybridization in 63 cases of resected pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Chromosomes, Human, Pair 17 / genetics. Gene Amplification / genetics. Gene Dosage / genetics. Genes, erbB-2 / genetics. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2009 Sep;54(9):2049-51 [19582575.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):102-8 [12373720.001]
  • [Cites] Oncology. 2001;61 Suppl 2:67-72 [11694790.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Oncologist. 1998;3(4):237-252 [10388110.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):137-48 [12170018.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Aug;2(8):356-64 [16265403.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):630-6 [15630697.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4737-45 [15570074.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):620-3 [14607699.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1125-34 [16096400.001]
  • [Cites] JOP. 2006 May 09;7(3):283-94 [16685109.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):119-24 [8617452.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):123-9 [10029438.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):254-64 [8617201.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):520-5 [11839672.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1593-7 [12168842.001]
  • [Cites] Pancreas. 1997 Apr;14(3):229-36 [9094152.001]
  • [Cites] Histopathology. 2001 Feb;38(2):96-104 [11207822.001]
  • [Cites] Cancer Invest. 2004;22(5):706-12 [15581051.001]
  • [Cites] Science. 1985 Sep 6;229(4717):974-6 [2992089.001]
  • [Cites] APMIS. 2003 Mar;111(3):444-50 [12752225.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):766-70 [15981817.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7972-7 [15585632.001]
  • [Cites] Mayo Clin Proc. 2002 Feb;77(2):148-54 [11838648.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • (PMID = 18463983.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hara H, Suda K, Oyama T: Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas. Acta Cytol; 2005 Nov-Dec;49(6):611-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas.
  • OBJECTIVE: To clarify 2 cytologic patterns: severe ductal dysplasia (SD)/carcinoma in situ (CIS) and invasive components of invasive ductal adenocarcinoma of the pancreas (IDAP).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450900.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Fan F, Lai EC, Xie F, Yang JM, Xu F, Kan T, Shen RX, Yang XY, Lau Wan Y, Wu MC: Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy. Hepatogastroenterology; 2010 May-Jun;57(99-100):635-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy.
  • RESULTS: Thirteen patients (32.5%) had adenomas, 4 (10%) borderline IPMN, 18 (45%) carcinoma in situ, and 5 (12.5%) invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698241.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Zhang XQ, Huang XF, Mu SJ, An QX, Xia AJ, Chen R, Wu DC: Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl; 2010 May;12(3):390-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Contraceptive Agents, Male / pharmacology. Gossypol / pharmacology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, CD31 / metabolism. Apoptosis / drug effects. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Humans. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Microvessels / drug effects. Microvilli / drug effects. Microvilli / ultrastructure. Neovascularization, Pathologic / drug therapy. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2. Tetrazolium Salts. Thiazoles. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3791-9 [11268456.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2179-88 [19528479.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Food. 2003 Winter;6(4):291-9 [14977436.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):91-100 [15015581.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23 [15361189.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4243-7 [2440560.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Semin Diagn Pathol. 1993 Nov;10(4):302-13 [7511250.001]
  • [Cites] Oncology. 1995 Mar-Apr;52(2):134-9 [7854773.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Semin Urol Oncol. 1998 Aug;16(3):118-23 [9741415.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):940-4 [9764587.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):171-80 [10096426.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):361-71 [10453280.001]
  • [Cites] Urology. 1999 Sep;54(3):479-85 [10475358.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):197-205 [15713891.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9350-9 [16227586.001]
  • [Cites] Pancreas. 2005 Nov;31(4):317-24 [16258364.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):163-72 [16611409.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1925-33 [16827126.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Life Sci. 2007 Jan 30;80(8):767-74 [17156797.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):323-31 [18840529.001]
  • [Cites] Eur Cytokine Netw. 2008 Dec;19(4):176-84 [19103523.001]
  • [Cites] J Surg Res. 2009 Jun 1;154(1):9-12 [19084241.001]
  • [Cites] Scand J Urol Nephrol. 2001 Dec;35(6):437-52 [11848422.001]
  • (PMID = 20081872.001).
  • [ISSN] 1745-7262
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Contraceptive Agents, Male; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC3739255
  •  go-up   go-down


27. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn; 2010 Nov;12(6):780-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatobiliary tract strictures result either from malignancies of the biliary tract and pancreas or from nonmalignant etiopathogenesis.
  • The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma.
  • Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54).
  • KRAS mutations and polysomic (ie, positive) FISH results were identified in 24 (69%) and 22 (63%) pancreatic adenocarcinoma specimens, respectively, with a combined sensitivity of 86% (30/35).
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Cholangiopancreatography, Endoscopic Retrograde. Cytodiagnosis / methods. DNA Mutational Analysis / methods. In Situ Hybridization, Fluorescence / methods. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jun 25;93(3):229-35 [11391612.001]
  • [Cites] Gut. 2001 Mar;48(3):403-8 [11171833.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):629-35 [10100716.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):412-20 [15467712.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1315-20 [16311354.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Diagn Cytopathol. 2007 Apr;35(4):218-24 [17351944.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10 [18090159.001]
  • [Cites] Liver Int. 2008 Jan;28(1):12-27 [18031477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1097-101 [18286693.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Oncol Res. 2008;17(4):151-7 [18773859.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1270-8 [18995218.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2180-6 [19232347.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Arch Pathol Lab Med. 2009 Oct;133(10):1600-6 [19792050.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):543-52 [19815694.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):583-9 [19815696.001]
  • [Cites] Pancreas. 2009 Nov;38(8):890-5 [19752775.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Diagn Cytopathol. 2002 May;26(5):273-7 [11992366.001]
  • (PMID = 20864634.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2963905
  •  go-up   go-down


28. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK: MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol; 2006 Mar;186(3):687-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate factors predictive of the presence of invasive carcinoma associated with intraductal papillary mucinous neoplasm (IPMN) of the pancreas on MDCT.
  • MATERIALS AND METHODS: Preoperative MDCT of 36 consecutive patients (23 men, 13 women; mean age, 66.6 years) who had undergone surgical resection and had a pathologic diagnosis of IPMN were retrospectively assessed.
  • RESULTS: Pathologic analysis revealed carcinoma in situ in seven patients (19%) and invasive carcinoma in 15 patients (42%) arising from the IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498096.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


29. Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M, Mizukami Y, Yanagawa N, Fujii T, Obara T, Okumura T, Kohgo Y: Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut; 2008 Mar;57(3):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results.
  • BACKGROUND AND AIMS: Although branch duct intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas without mural nodules are frequently observed in asymptomatic subjects, the natural history of these lesions has never been studied.
  • Histological analysis revealed three cases classified as adenoma and one as carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):598-9 [18797440.001]
  • [CommentIn] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • (PMID = 17660227.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Bersch VP, Osvaldt AB, Edelweiss MI, Schumacher Rde C, Wendt LR, Abreu LP, Blom CB, Abreu GP, Costa L, Piccinini P, Rohde L: Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. Pancreas; 2009 Jan;38(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice.
  • Pancreatic adenocarcinoma has a higher frequency in the DMBA-n group (14 [51.9%]) than in the DMBA-e (4 [16.7%]) and DMBA-s (4, 13.3%) groups.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinogens / toxicity. Carcinoma in Situ / etiology. Nicotine / toxicity. Pancreatic Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. NICOTINE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824948.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


31. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Ovary / cytology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Hara H, Suda K: Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma. Am J Clin Pathol; 2008 Jan;129(1):115-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
  • Invasive ductal adenocarcinoma (IDA) of the pancreas (IDAP) originating from the ductal gland has a poor prognosis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Hyperplasia / pathology. Mucins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089497.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


33. Ott C, Heinmöller E, Gaumann A, Schölmerich J, Klebl F: [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma]. Med Klin (Munich); 2007 Feb 15;102(2):127-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma].
  • Pancreatic intraepithelial neoplasias (PanIN) have been recognized as precursor lesions of ductal adenocarcinoma, and are classified into different grades from PanIN-1A, -1B, -2, to -3.
  • Becoming invasive, some of these tumors appear as ductal adenocarcinoma, others as colloid carcinoma with a much better prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous. Adenocarcinoma, Papillary. Carcinoma in Situ. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor. Disease Progression. Humans. Middle Aged. Mutation. Pancreas / pathology. Pancreatic Ducts / pathology. Precancerous Conditions / pathology. Prognosis. Retrospective Studies. Risk Factors. Terminology as Topic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323019.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


34. Papaziogas B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Paraskevas G, Argiriadou H, Atmatzidis S, Atmatzidis K: Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. Cases J; 2008;1(1):249
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of pancreatic tissue outside the confines of the main gland, without anatomic or vascular connections between them, is a congenital abnormality referred to as heterotopic pancreas.
  • A heterotopic pancreas in the gastrointestinal tract is usually discovered incidentally and the risk of its malignant transformation is extremely low.
  • In this study, we describe the first case of endoepithelial carcinoma arising in a gastric heterotopic pancreas of a 56-year old woman in Greece.
  • Microscopically, an endoepithelial (in situ) carcinoma of the gastric antrum was determined, which in places turned into an microinvasive endomucosal adenocarcinoma.
  • It also incidentally demonstrated heterotopic pancreatic ducts, detected within the mucosa to the muscularis propria of the same region of the stomach, in which an endoepithelial (in situ) carcinoma was evolving.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1995 May;33(5):260-4 [7610694.001]
  • [Cites] Histopathology. 1992 May;20(5):433-5 [1587493.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1289-92 [1812259.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):196-8 [2032610.001]
  • [Cites] Postgrad Med J. 1988 Oct;64(756):801-3 [3255924.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):593-9 [894461.001]
  • [Cites] Can J Surg. 1976 Sep;19(5):413-4 [974927.001]
  • [Cites] Arch Surg. 1974 Dec;109(6):762-5 [4420439.001]
  • [Cites] J Korean Med Sci. 2004 Feb;19(1):145-8 [14966359.001]
  • [Cites] Can J Surg. 2001 Dec;44(6):407 [11764870.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):549-54 [11472568.001]
  • [Cites] West J Med. 1981 Jul;135(1):57-62 [7257381.001]
  • (PMID = 18928565.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577107
  •  go-up   go-down


35. Uehara H, Nakaizumi A, Iishi H, Takenaka A, Eguchi H, Ohigashi H, Ishikawa O: In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas; 2008 Apr;36(3):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases.
  • In the present study using an in situ TRAP assay, we investigated the specificity of telomerase activity in pancreatic juice for pancreatic cancer.
  • METHODS: Pancreatic juice were obtained endoscopically at endoscopic retrograde cholangiopancreatography from 10 patients with pancreatic cancer, 4 with intraductal papillary neoplasm, and 3 with normal pancreas.
  • In situ telomerase activity in pancreatic juice samples was examined by in situ TRAP assay and was compared with the results of cytological examination.
  • RESULTS: Of 10 samples from pancreatic cancer, high telomerase activity in situ was detected in 9 and cancer cells in 7.
  • Of 4 samples from intraductal papillary neoplasm, low telomerase activity in situ and mild atypical cells were detected in 2.
  • Telomerase activity in situ was detected in none of 3 samples from normal pancreas.
  • CONCLUSIONS: Detection of in situ telomerase activity in pancreatic juice might help discriminate pancreatic cancer from other pancreatic diseases.
  • [MeSH-major] Pancreatic Diseases / diagnosis. Pancreatic Diseases / enzymology. Pancreatic Juice / enzymology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / enzymology. Aged. Base Sequence. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / enzymology. Case-Control Studies. DNA Primers / genetics. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362835.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


36. Kalinina T, Güngör C, Thieltges S, Möller-Krull M, Penas EM, Wicklein D, Streichert T, Schumacher U, Kalinin V, Simon R, Otto B, Dierlamm J, Schwarzenbach H, Effenberger KE, Bockhorn M, Izbicki JR, Yekebas EF: Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer; 2010;10:295
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.
  • Numerous genes were overexpressed, some of which have previously been implicated in pancreatic adenocarcinoma (GATA6, IGFBP3, IGFBP6), while others were detected for the first time (MEMO1, RIOK3).
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Culture Techniques. Cell Line, Tumor. Cell Proliferation. Cell Separation. Cell Shape. DNA-Binding Proteins / deficiency. DNA-Binding Proteins / genetics. Dose-Response Relationship, Drug. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Pore Forming Cytotoxic Proteins / deficiency. Pore Forming Cytotoxic Proteins / genetics. Time Factors. Tumor Burden. Xenograft Model Antitumor Assays


37. Adsay NV, Basturk O, Cheng JD, Andea AA: Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol; 2005 Oct;15(4):254-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
  • Invasive ductal adenocarcinoma (DA) is the most important and constitutes the vast majority (>85%) of pancreatic tumors.
  • A similar (in situ) neoplastic spectrum also characterizes intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, which are cystic ductal-mucinous tumors with varying degrees of papilla formation, and may be associated with invasive carcinoma.
  • Colloid carcinoma of the pancreas appears to be a clinicopathologically distinct tumor with indolent behavior.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cystadenocarcinoma / pathology. DNA, Neoplasm. Gene Expression Regulation, Neoplastic. Gene Silencing. Genes, Neoplasm. Humans. Mutation. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Up-Regulation


38. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, Hruban RH, Goggins M: Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol; 2008 Dec;21(12):1499-507
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.
  • Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer death and is usually diagnosed late.
  • Intraductal papillary mucinous neoplasms are an increasingly recognized precursor to invasive ductal adenocarcinoma of the pancreas.
  • Normal pancreas was also obtained from 27 patients with intraductal papillary mucinous neoplasms or pancreatic adenocarcinomas and 10 patients with well-differentiated pancreatic endocrine neoplasms.
  • Carcinomas (intraductal papillary mucinous neoplasms with carcinoma in situ or their associated infiltrating adenocarcinoma) had significantly more methylated genes (71+/-19%) than low-grade (low and moderate dysplasia) intraductal papillary mucinous neoplasms (44+/-26%, P<0.0001).
  • The detection of aberrant methylation in pancreatic cystic lesions could facilitate the diagnosis of intraductal papillary mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):548-65 [16472607.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):365-72 [12105864.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5 [17481526.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6019-25 [17947463.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):863-9 [17899180.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):243-9 [18027059.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):850-8 [15592528.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):573-83 [15701843.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • (PMID = 18820670.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-140011; United States / NCI NIH HHS / CA / CA062924-149002; United States / NCI NIH HHS / CA / CA062924-150011; United States / NCI NIH HHS / CA / P50 CA062924-149002; United States / NCI NIH HHS / CA / P50 CA062924-159002; United States / NCI NIH HHS / CA / P50 CA062924-150011; United States / NCI NIH HHS / CA / CA062924-159002; United States / NCI NIH HHS / CA / CA062924-140011
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  • [Other-IDs] NLM/ NIHMS105558; NLM/ PMC2678809
  •  go-up   go-down


39. Liang S, Yang ZL: [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb;32(1):109-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats].
  • METHODS: Dimethylbenzanthracene (DMBA) was directly implanted into the parenchyma of pancreas in SD rats (Group A), and DMBA combined with trichostatin (TSA) was implanted in the intervention group (Group B).
  • The expression of KiSS-1mRNA was assayed by in situ hybridization. RESULTS:.
  • (1) The incidence of pancreatic cancer in Group A within 3 - 5 months was 48.7% (18/37), including 17 cases of pancreatic ductal adenocarcinoma and 1 case of fibrosarcoma.
  • The incidence of pancreatic cancer in Group B was 33.3% (12/36), including 11 pancreatic ductal adenocarcinoma and 1 fibrosarcoma.
  • The positive rates of KiSS-1mRNA in Group A or Group B with ductal adenocarcinoma were significantly lower than those in Group A or Group B without ductal adenocarcinoma (P<0.01).
  • CONCLUSION: DMBA directly implanted into the parenchyma of pancreas can obtain an ideal pancreatic cancer model with high incidence in a short time.
  • TSA may have an inhibitive effect on the carcinogenesis and the growth of pancreatic ductal adenocarcinoma in rats, and KiSS-1 may play an important role in inhibiting the invasion and metastasis of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Pancreas / metabolism. Pancreatic Neoplasms / genetics. Proteins / genetics
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Female. Gene Expression Regulation, Neoplastic. In Situ Hybridization. Kisspeptins. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344598.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Kiss1 protein, rat; 0 / Kisspeptins; 0 / Proteins; 0 / RNA, Messenger; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


40. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer; 2006 Apr 15;106(8):1677-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to use a series of algorithms called AQUA that quantitatively assesses protein expression on tissue microarrays (TMAs) to compare in situ expression of VEGF and its primary receptors, VEGF receptor 1 (FLT-1) and VEGF receptor 1 (FLK-1), on a pancreatic cancer TMA.
  • METHODS: TMAs were constructed by arraying 1.5-mm cores from 76 samples of pancreatic adenocarcinoma (1996-2002) that were obtained from the archives of the Yale Department of Pathology.
  • CONCLUSIONS: VEGF and its 2 principal receptors were expressed to varying degrees in tumors of the pancreas.
  • [MeSH-major] Adenocarcinoma / chemistry. Pancreatic Neoplasms / chemistry. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-1 / analysis. Vascular Endothelial Growth Factor Receptor-2 / analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16532435.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


41. Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG: Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer; 2009 Aug 15;125(4):942-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma carries an ominous prognosis and has little effective treatment.
  • Several studies have demonstrated that the potently antiapoptotic phosphatidyl inositol 3'-kinase (PI3K)-protein kinase B/AKT pathway is active in pancreas cancer.
  • We screened several cell permeable peptides from the N-terminal domain of CTMP (termed TAT-CTMP1-4) in vitro and found one that caused significant apoptosis in pancreatic adenocarcinoma cell lines.
  • A screening of various cell and tissue types revealed that the proapoptotic activity was highest in pancreatic adenocarcinoma.
  • We further showed that TAT-CTMP4 could augment either gemcitabine chemotherapy or radiation therapy, standard therapies for pancreas cancer.
  • Pancreatic adenocarcinoma xenografts treated with a single dose of TAT-CTMP4 demonstrated a marked increase in caspase-3 positive tumor cells when compared with untreated controls.
  • Additionally, pancreatic adenocarcinoma allografts treated with intratumoral TAT-CTMP and systemic gemcitabine displayed a significantly smaller tumor burden while undergoing treatment than mice in control groups (p < 0.001).
  • These data indicate that inhibiting AKT with CTMP may be of therapeutic benefit in the treatment of pancreatic adenocarcinoma and, when combined with established therapies, may result in an increase in tumor cell death.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6105-11 [11507060.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3269-75 [11595724.001]
  • [Cites] Science. 2001 Oct 12;294(5541):374-80 [11598301.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Int J Oncol. 1998 Jan;12(1):141-52 [9454898.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):989-97 [12481421.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):346-54 [12538487.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Bioconjug Chem. 2003 Mar-Apr;14(2):368-76 [12643747.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):7-11 [14749121.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2950-66 [15077156.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1135-9 [7653991.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1997 Jan;27(1):47-57 [9002166.001]
  • [Cites] Science. 1999 Apr 9;284(5412):339-43 [10195903.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S69-77 [15316751.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):5-10 [15651171.001]
  • [Cites] Gen Physiol Biophys. 2004 Jun;23(2):209-29 [15696860.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):227-38 [15766661.001]
  • [Cites] Z Gastroenterol. 2005 Oct;43(10):1133-9 [16220453.001]
  • [Cites] Infect Immun. 2005 Dec;73(12):8275-81 [16299324.001]
  • [Cites] J Androl. 2006 Mar-Apr;27(2):285-93 [16474026.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5471-7 [16622015.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 6;355(2):501-7 [17307150.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):566-72 [17414605.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1763-71 [17206479.001]
  • [Cites] Pancreas. 2007 Oct;35(3):e16-26 [17895832.001]
  • [Cites] Oncogene. 2007 Oct 25;26(49):7038-48 [17486061.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Nov;293(5):C1576-85 [17615157.001]
  • [Cites] Gene Ther. 2007 Dec;14(24):1721-30 [17960162.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):431-7 [11485901.001]
  • (PMID = 19405118.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM044118; United States / NIGMS NIH HHS / GM / GM44118; United States / NCI NIH HHS / CA / T32 CA009621; United States / NCI NIH HHS / CA / T32 CA09621; United States / NIGMS NIH HHS / GM / GM044118-08; United States / NIGMS NIH HHS / GM / GM055194-03; United States / NIGMS NIH HHS / GM / R01 GM044118-08; United States / NCI NIH HHS / CA / T32 CA009621-11; United States / NIGMS NIH HHS / GM / R01 GM055194-03; United States / NIGMS NIH HHS / GM / R01 GM055194; United States / NIGMS NIH HHS / GM / GM55194; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIGMS NIH HHS / GM / R37 GM044118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / tat Gene Products, Human Immunodeficiency Virus; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.2.- / THEM4 protein, human; EC 3.1.2.- / Thiolester Hydrolases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS109118; NLM/ PMC3645501
  •  go-up   go-down


42. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer; 2007 Mar 1;120(5):1046-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This has been accomplished with the application of real-time PCR profiling of over 200 microRNA precursors on specimens of human pancreatic adenocarcinoma, paired benign tissue, normal pancreas, chronic pancreatitis and nine pancreatic cancer cell lines.
  • Hierarchical clustering was able to distinguish tumor from normal pancreas, pancreatitis and cell lines.
  • The PAM algorithm correctly classified 28 of 28 tumors, 6 of 6 normal pancreas and 11 of 15 adjacent benign tissues.
  • Reverse transcription in situ PCR showed that three of the top differentially expressed miRNAs (miR-221, -376a and -301) were localized to tumor cells and not to stroma or normal acini or ducts.
  • Aberrant microRNA expression may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [Cites] Science. 2001 Sep 14;293(5537):2087-92 [11557892.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12754-9 [10535995.001]
  • [Cites] Dev Cell. 2003 Aug;5(2):351-8 [12919684.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Trends Biochem Sci. 2004 Sep;29(9):462-8 [15337119.001]
  • [Cites] Pancreas. 2004 Nov;29(4):254-63 [15502640.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52361-5 [15504739.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12023-8 [16099838.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • (PMID = 17149698.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107435-02; United States / NCI NIH HHS / CA / R21 CA107435-02; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / CA107435; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / R21 CA107435
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS82895; NLM/ PMC2680248
  •  go-up   go-down


43. Saif MW: Primary pancreatic lymphomas. JOP; 2006;7(3):262-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An accurate cytopathologic diagnosis by fine-needle aspiration (FNA) is imperative because the primary treatment is non-surgical.
  • FNA coupled with flow cytometry analysis appears to be highly accurate in the diagnosis of primary pancreatic lymphomas.
  • Fluorescence in-situ hybridisation technique has been established its role in the diagnosis of lymphoid malignancies, including primary pancreatic lymphomas.
  • Primary pancreatic lymphomas has a much better prognosis than adenocarcinoma of the pancreas.
  • [MeSH-major] Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685107.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 40
  •  go-up   go-down


44. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, Brentnall TA, Lüttges J, Klöppel G, Lemoine NR: Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol; 2005 Jan;166(1):81-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S100P is a member of the S100 family of calcium-binding proteins and there have been several recent reports of its overexpression in pancreatic ductal adenocarcinoma (PDAC).
  • By in situ hybridization, S100PBPR transcript was found in islet cells but not duct cells of the healthy pancreas.
  • Both S100P and S100PBPR were detected by quantitative real-time polymerase chain reaction in pancreatic intraepithelial neoplasia (PanIN) and PDAC samples, and in situ hybridization revealed the presence of S100PBPR transcript in malignant PDAC cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Base Sequence. Calcium / metabolism. Cloning, Molecular. DNA Primers. Disease Progression. Humans. In Situ Hybridization. Magnesium / metabolism. Polymerase Chain Reaction. RNA, Messenger / genetics. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Jul 4;21(29):4587-94 [12085237.001]
  • [Cites] Am J Clin Pathol. 1994 Jun;101(6):684-8 [8209852.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28848-52 [12042313.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):231-40 [10639564.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Biochemistry. 2000 Aug 8;39(31):9533-9 [10924150.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6134-41 [11085537.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4923-32 [11406572.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7437-46 [11704875.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8830-7 [11751405.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1256-60 [11888886.001]
  • [Cites] Verh Dtsch Ges Pathol. 2001;85:219-28 [11894402.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] Protein Sci. 2002 Jun;11(6):1367-75 [12021435.001]
  • [Cites] Anat Rec. 2002 May 1;267(1):60-9 [11984793.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):818-23 [12679940.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2372-84 [12808036.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):263-70 [12824920.001]
  • [Cites] Cell Mol Life Sci. 2003 Jun;60(6):1180-99 [12861384.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2003;4:237-56 [14527303.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):508-17 [12942322.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Aug;2(3):467-70 [14599962.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5059-65 [14617629.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1291-5 [7992834.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):119-24 [8617452.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1763-70 [8669463.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Anticancer Drugs. 1998 Apr;9(4):311-7 [9635921.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] J Mol Biol. 1998 Oct 30;283(3):679-94 [9784376.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):123-9 [10029438.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:64-8 [10436788.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Jun;22(2):307-13 [12866582.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1531-8 [14716296.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2385-400 [14767473.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Eur J Biochem. 1992 Jul 15;207(2):541-7 [1633809.001]
  • [Cites] Am J Pathol. 1994 May;144(5):889-95 [8178941.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • (PMID = 15632002.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Carrier Proteins; 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / S100P protein, human; 0 / S100PBP protein, human; I38ZP9992A / Magnesium; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1602285
  •  go-up   go-down


45. Marrache F, Pendyala S, Bhagat G, Betz KS, Song Z, Wang TC: Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut; 2008 Aug;57(8):1113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic pancreatitis is a known risk factor for pancreatic adenocarcinoma.
  • BMDCs did engraft in the pancreas.
  • In the absence of preneoplastic lesions, BMDCs contribute at a very low level to the ductal epithelium of the chronically inflamed pancreas.
  • [MeSH-minor] Animals. Bone Marrow Transplantation. Ceruletide. Disease Models, Animal. Immunoenzyme Techniques. In Situ Hybridization. Male. Mice. Mice, Inbred C57BL. Microscopy, Confocal. Y Chromosome

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367560.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; 888Y08971B / Ceruletide
  •  go-up   go-down


46. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA: Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther; 2005 Mar;4(3):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.
  • Using nonradioactive in situ hybridization, we evaluated the gene expression patterns of three genes previously shown to be robust markers of the juxtatumoral stroma within eight infiltrating ductal adenocarcinoma of the pancreas (ApoC1, ApoD and MMP11), and compared these patterns to those associated with seven infiltrating colloid and tubular carcinomas arising in association with intraductal papillary mucinous neoplasms (IPMNs), a histologically distinct form of primary carcinoma of the pancreas, two surgically resected samples of chronic pancreatitis and two surgically resected pancreatic cancer liver metastases.
  • Robust juxtatumoral stromal expression was noted for all three markers within all eight conventional infiltrating ductal adenocarcinoma tissues, but not in samples of chronic pancreatitis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apolipoprotein C-I. Apolipoproteins / analysis. Apolipoproteins / genetics. Apolipoproteins C / analysis. Apolipoproteins C / genetics. Apolipoproteins D. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / secondary. Cell Communication / genetics. Gene Expression. Glycoproteins / analysis. Glycoproteins / genetics. Humans. In Situ Hybridization. Liver Neoplasms / chemistry. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Matrix Metalloproteinase 11. Membrane Transport Proteins / analysis. Membrane Transport Proteins / genetics. Metalloendopeptidases / analysis. Metalloendopeptidases / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876873.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA1066110; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / Apolipoprotein C-I; 0 / Apolipoproteins; 0 / Apolipoproteins C; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


47. Schnelldorfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, Chari ST, Farnell MB: Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg; 2008 Jul;143(7):639-46; discussion 646
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
  • HYPOTHESIS: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized disease of the pancreas.
  • RESULTS: Of 208 patients (mean age, 66 years) with IPMN of the pancreas, 168 underwent partial pancreatectomy, and 40 underwent total pancreatectomy; 88 were classified as having adenoma, 38 as having borderline neoplasm, 19 as having carcinoma in situ, and 63 as having invasive carcinoma.
  • Patients with invasive IPMN had a similar 5-year survival compared with a matched cohort with ductal adenocarcinoma (31% vs 24%; P = .26).
  • Invasive IPMN behaves as aggressively as ductal adenocarcinoma, but resection seems to provide the only potential for cure.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645105.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Amillet JM, Ferbus D, Real FX, Antony C, Muleris M, Gress TM, Goubin G: Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Hum Pathol; 2006 Mar;37(3):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Absent or very faint expression was observed in normal pancreas cell extracts.
  • Immunohistochemical analysis of Rab20 in tissues showed low or absent expression in normal pancreas and stronger expression in 15 of 18 exocrine pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Pancreas, Exocrine / metabolism. Pancreatic Neoplasms / genetics. rab GTP-Binding Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / ultrastructure. HeLa Cells. Humans. Immunoenzyme Techniques. Molecular Sequence Data. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Sequence Homology, Amino Acid

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613320.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.6.1- / Rab20 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


49. Abe K, Suda K, Arakawa A, Yamasaki S, Sonoue H, Mitani K, Nobukawa B: Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. Pancreas; 2007 Jan;34(1):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Either the loss of p16INK4A expression or the overexpression of p53 was much more frequently observed among PanIN-3 than among carcinoma in situ in IPMN (P = 0.046 and 0.008, respectively).
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Pancreatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198188.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


50. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Namikawa T, Okamoto K, Okamoto N, Kosaki T, Onishi S, Araki K: Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol; 2006 Feb;21(2):462-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to identify preoperative features that may be predictors of malignant IPMN, and to define the medical management of IPMN of the pancreas.
  • METHODS: A total of 23 patients who underwent surgical resection for IPMN of the pancreas at Kochi Medical School between 1982 and 2004 were examined.
  • RESULTS: Among the 23 patients, 12 had IPMN adenoma, three had borderline IPMN, four had IPMN with carcinoma in situ, and four had IPMN with invasive carcinoma.
  • These results suggest that the following IPMN of the pancreas should be resected: (i) IPMN of the pancreas situated in the main duct;.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509876.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


51. Buchholz M, Braun M, Heidenblut A, Kestler HA, Klöppel G, Schmiegel W, Hahn SA, Lüttges J, Gress TM: Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene; 2005 Oct 6;24(44):6626-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours.
  • Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.
  • [MeSH-major] Carcinoma in Situ / genetics. Pancreatic Neoplasms / genetics. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103885.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger
  •  go-up   go-down


52. Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist; 2010;15(12):1294-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.
  • Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas.
  • For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2004 Oct;29(3):212-7 [15367887.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Dig Surg. 2008;25(1):46-51 [18292661.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1127-32 [18299945.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):474-81 [17680299.001]
  • [Cites] Pancreatology. 2008;8(3):277-84 [18497541.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):802-7 [18716113.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41 [18843017.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3187-92 [18766406.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):543-7 [12297771.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):234-42 [18040749.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3193-8 [18784959.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1499-507 [18820670.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S203-9 [19179158.001]
  • [Cites] Pancreas. 2009 Mar;38(2):131-6 [18981954.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pathologe. 2005 Feb;26(1):22-30 [15624092.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4681-8 [16000561.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1034-42 [15832194.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):112-6 [16639605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 [16858538.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Pancreatology. 2006;6(6):626-34 [17135772.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] JOP. 2007;8(2):206-13 [17356245.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95 [17350894.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(1):35-48 [19258185.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Pancreatology. 2009;9(1-2):34-44 [19077453.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] Radiology. 2009 Oct;253(1):106-15 [19703865.001]
  • [Cites] Pancreatology. 2009;9(5):631-8 [19657218.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):531-40 [19818780.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):477-82 [20142730.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Pancreas. 2010 Apr;39(3):308-14 [19924021.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Langenbecks Arch Surg. 2003 Dec;388(6):392-400 [12910422.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • (PMID = 21147870.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227924
  •  go-up   go-down


53. te Velde EA, Franke AC, van Hillegersberg R, Elshof SM, de Weger RW, Borel Rinkes IH, van Diest PJ: HER-family gene amplification and expression in resected pancreatic cancer. Eur J Surg Oncol; 2009 Oct;35(10):1098-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue of 45 resected patients was analyzed for all HER-family 1-4 expression by immunohistochemistry and HER-2 gene amplification was assessed by multiplex ligation-dependent probe amplification and chromogenic in situ hybridization.
  • HER-3, HER-4 is physiologically expressed in the normal pancreas and loss of cytoplasmic HER-3 and HER-4 expression was seen in 33/45 (73%) and 8/45 (18%) of pancreatic cancers.
  • HER-3 and HER-4 are expressed in the normal pancreas but expression is lost in pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Genes, erbB-2. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / metabolism


54. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling


55. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis; 2008 Jun;29(6):1096-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
  • Thus, simultaneous inhibition of both tyrosine kinases represents a potential novel therapeutic approach in human pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 [8832401.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):793-9 [8707856.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7162-8 [9507031.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2571-85 [9566877.001]
  • [Cites] Trends Cell Biol. 1998 Apr;8(4):151-7 [9695829.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):547-60 [9786962.001]
  • [Cites] Cell Growth Differ. 1998 Dec;9(12):999-1005 [9869300.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5422-8 [10026153.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3868-76 [15867386.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):505-15 [16069815.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6 [16360004.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1446-54 [16452200.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):787-96 [16648548.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1357-67 [17431114.001]
  • [Cites] Exp Cell Res. 1996 Feb 1;222(2):298-303 [8598217.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38978-87 [12167618.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3846-51 [12458213.001]
  • [Cites] Cell Signal. 2003 Jun;15(6):575-83 [12681445.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Mol Cancer Res. 2003 Aug;1(10):755-64 [12939401.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92 [14623342.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):559-67 [14629195.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4361-71 [15121855.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2007-11 [7743492.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Mar 27;220(3):886-90 [8607861.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):413-8 [9052982.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):249-56 [10806474.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2417-23 [10873094.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30597-604 [10899173.001]
  • [Cites] Growth Horm IGF Res. 2002 Aug;12(4):193-7 [12175651.001]
  • [Cites] Pancreas. 1997 Nov;15(4):367-73 [9361090.001]
  • (PMID = 18263593.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113766-01A2; United States / NCI NIH HHS / CA / K08 CA113766; United States / NCI NIH HHS / CA / CA113766-02; United States / NCI NIH HHS / CA / K08 CA113766-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.2 / Focal Adhesion Kinase 1
  • [Other-IDs] NLM/ PMC2902396
  •  go-up   go-down


56. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology; 2007 Jul;133(1):72-9; quiz 309-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in branch ducts are thought to be less aggressive than their main-duct counterparts, and guidelines for their conservative management were recently proposed.
  • RESULTS: Sixty-six patients (45.5%) had adenoma, 47 (32%) borderline tumors, 16 (11%) carcinoma in situ, and 16 (11%) invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Practice Guidelines as Topic / standards. Survival Analysis


57. Janot MS, Kersting S, Chromik AM, Tannapfel A, Uhl W: [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis]. Zentralbl Chir; 2010 Aug;135(4):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis].
  • INTRODUCTION: When patients who underwent a Whipple operation because of a tumour of the pancreas develop symptoms of chronic ileus several months after surgery, the most common cause is a relapse of tumour growth or a peritoneal carcinomatosis.
  • In this paper we report that secondary amyloidosis of the small intestine can produce similar symptoms and has to be evaluated as a rare differential diagnosis in chronic ileus.
  • In two patients surgery was performed due to carcinoma in situ and in one patient due to benign cystadenoma of the pancreas.
  • Surgeons have to keep in mind that amyloidosis is a possible differential diagnosis in addition to relapse of tumour growth and peritoneal carcinomatosis in these patients.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Amyloidosis / diagnosis. Cystadenoma, Mucinous / surgery. Ileus / diagnosis. Intestinal Diseases / diagnosis. Intestine, Small. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Tissue Adhesions / diagnosis. Tissue Adhesions / pathology. Tissue Adhesions / surgery

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart ˙ New York.
  • (PMID = 20464655.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Wendt LR, Osvaldt AB, Bersch VP, Schumacher Rde C, Edelweiss MI, Rohde L: Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine. Acta Cir Bras; 2007 May-Jun;22(3):202-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine.
  • In all animals, 1 mg of DMBA was implanted into the head of the pancreas.
  • After 30 days, euthanasia was performed; excised pancreata were then fixed in formalin, stained with hematoxylin-eosin and categorized as follows: normal ducts, reactive hyperplasia, PanIN-1A, PanIN-1B, PanIN-2, PanIN-3 or adenocarcinoma.
  • Adenocarcinoma was detected in 15% of animals in the caffeine group, 16.6% in the water group, 23.8% in the alcohol + caffeine group and 52.9% in the alcohol group (P<0.05).
  • CONCLUSIONS: The experimental pancreatic carcinogenesis mouse model using DMBA effectively induces PanIN lesions and pancreatic adenocarcinoma.
  • This study verified the association between alcohol use and pancreatic adenocarcinoma; caffeine did not present the same effect.

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. ETHANOL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546293.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Carcinogens; 3G6A5W338E / Caffeine; 3K9958V90M / Ethanol; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


59. Haugk B: Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology; 2010 Oct;57(4):503-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cancer is a heterogeneous group in which pancreatic ductal adenocarcinoma (PDAC) is the most common.
  • Great advances in the understanding of pancreatic carcinogenesis have opened avenues for diagnosis and chemoprevention.
  • However, access to the pancreas is limited, molecular tests are at the early stages and too little is known about the natural history of early PanINs to justify resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Early Detection of Cancer. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20875068.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Okada K, Imaizumi T, Hirabayashi K, Matsuyama M, Yazawa N, Dowaki S, Tobita K, Ohtani Y, Kawaguchi Y, Tanaka M, Inokuchi S, Makuuchi H: The distance of tumor spread in the main pancreatic duct of an intraductal papillary-mucinous neoplasm: where to resect and how to predict it. J Hepatobiliary Pancreat Sci; 2010 Jul;17(4):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The surgical decision regarding where to resect the pancreas is an important judgement that is directly linked to the surgical procedure.
  • An appropriate surgical margin to resect intraductal papillary-mucinous neoplasm (IPMN) of the pancreas based on the distance of tumor spread (DTS) in the main pancreatic duct has not been adequately documented.
  • The dysplastic state of the epithelium was judged as positive for carcinoma in situ (high-grade dysplasia) or adenoma (very low to moderate dysplasia) and judged as negative for hyperplasia or normal.
  • There has been no evidence of local recurrence in the remnant pancreas.
  • CONCLUSION: Distance of tumor spread offered important insights about the appropriate site to resect the pancreas and the positive rate at the cut end margin in IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714841.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB: Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim Biophys Acta; 2007 Jul;1770(7):1021-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic adenocarcinoma is characterized by a poor prognosis and lack of response to conventional therapy.
  • [MeSH-minor] Blotting, Western. Caspase 3 / metabolism. Cell Line, Tumor. DNA Primers. Enzyme-Linked Immunosorbent Assay. Epoxy Compounds / pharmacology. Flow Cytometry. Humans. In Situ Nick-End Labeling. Leukotriene B4 / metabolism. Luciferases. Pancreas / cytology. Pancreas / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434678.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Diterpenes; 0 / Epoxy Compounds; 0 / Phenanthrenes; 0 / Proto-Oncogene Proteins c-bcl-2; 19ALD1S53J / triptolide; 1HGW4DR56D / Leukotriene B4; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


62. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • Positive criteria of increased uptake on 18-FDG PET was absent in 13 of 13 adenomas and 7 of 8 borderline IPMNs, but was present in 4 of 5 carcinoma in situ (80%) and in 20 of 21 invasive cancers (95%).
  • Conventional imaging technique was strongly suggestive of malignancy in 2 of 5 carcinomas in situ and in 13 of 21 invasive carcinomas (62%).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Ikeda S, Maeshiro K, Ryu S, Ogata K, Yasunami Y, Nakayama Y, Hamada Y: Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas; 2009 May;38(4):e102-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients.
  • OBJECTIVES: The diagnosis of small pancreatic cancer remains difficult.
  • Of the 175 patients, 23 (13%) had invasive carcinoma 2 cm or smaller based on histological measurements, 3 intraductal papillotubular adenocarcinoma, and 3 carcinoma in situ (CIS).
  • A definite diagnosis was obtained based on the findings of main duct stenosis or obstruction with marked stricture of the branch ducts (n = 18) and a filling defect in the main duct (n = 2).
  • CONCLUSIONS: Balloon spot pancreatography is an essential tool for the diagnosis of small ductal pancreatic cancer, and it also makes it possible to locate CIS lesions of the branch ducts.
  • [MeSH-major] Catheterization. Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / diagnosis. Female. Humans. Male. Middle Aged. Pancreatitis / diagnosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287333.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ohike N, Kim GE, Tajiri T, Krasinskas A, Basturk O, Coban I, Bandyopadhyay S, Morohoshi T, Goodman M, Kooby DA, Sarmiento JM, Adsay NV: Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases. Am J Surg Pathol; 2010 Dec;34(12):1731-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases.
  • BACKGROUND: There has been no uniform terminology for systematic analysis of mass-forming preinvasive neoplasms (which we term tumoral intraepithelial neoplasia) that occur specifically within the ampulla.
  • Here, we provide a detailed analysis of these neoplasms, which we propose to refer to as intra-ampullary papillary-tubular neoplasm (IAPN).
  • MATERIALS AND METHODS: Three hundred and seventeen glandular neoplasms involving the ampulla were identified through a review of 1469 pancreatoduodenectomies and 11 ampullectomies.
  • Eighty-two neoplasms characterized by substantial preinvasive exophytic component that grew almost exclusively (>75%) within the ampulla (in the ampullary channel or intra-ampullary portions of the very distal segments of the common bile duct or pancreatic duct) were analyzed. RESULTS:.
  • (1) Clinical: The mean age was 64 years, male/female ratio was 2.4, and mean tumor size was 2.7 cm. (2) Pathology: The tumors had a mixture of both papillary and tubular growth (each constituting at least 25% of the lesion) in 57%; predominantly (>75%) papillary in 23%, and predominantly (>75%) tubular in 20%.
  • High-grade dysplasia was present in 94% of cases, of which 39% showed focal (<25% of the lesion), 28% showed substantial (25% to 75%), and 27% showed extensive (>75%) high-grade dysplasia.
  • In terms of cell-lineage morphology, 45% had a mixture of patterns.
  • However, when evaluated with a forced-binary approach as intestinal (INT) versus gastric/pancreatobiliary (GPB) based on the predominant pattern, 74% were classified as INT and 26% as GPB. (3) Immunohistochemistry: Percent sensitivity/specificity of cell-lineage markers were, for INT phenotype: MUC2 85/78 and CDX2 94/61; and for GBP: MUC1 89/79, MUC5AC 95/69, and MUC6 83/76, respectively.
  • Cytokeratin 7 and 20 were coexpressed in more than half. (4) Invasive carcinoma: In 64 cases (78%), there was an associated invasive carcinoma.
  • Size of the tumor and amount of dysplasia correlated with the incidence of invasion.
  • Invasive carcinoma was of INT-type in 58% and of pancreatobiliary-type in 42%.
  • Cell lineage in the invasive component was the same as that of the preinvasive component in 84%.
  • All discrepant cases were pancreatobiliary-type invasions, which occurred in INT-type preinvasive lesions. (5) OUTCOME: The overall survival of invasive cases were significantly worse than that of noninvasive ones (57% vs. 93%; P=0.01); and 3 years, 69% versus 100% (P=0.08); and 5 years, 45% versus 100% (P=0.07), respectively.
  • When compared with 166 conventional invasive carcinomas of the ampullary region, invasive IAPNs had significantly better prognosis with a mean survival of 51 versus 31 months (P<0.001) and the 3-year survival of 69% versus 44% (P<0.01).
  • CONCLUSIONS: Tumoral intraepithelial neoplasia occurring within the ampulla are highly analogous to pancreatic or biliary intraductal papillary and tubular neoplasms as evidenced by their papillary and/or tubular growth, variable cell lineage, and spectrum of dysplastic change (adenoma-carcinoma sequence), and thus we propose to refer to these as IAPN.
  • IAPNs are biologically indolent; noninvasive examples show an excellent prognosis, whereas those with invasion exhibit a malignant but nevertheless significantly better prognosis than typical invasive ampullary carcinomas unaccompanied by IAPNs.
  • Twenty eight percent (64 of 230) of invasive carcinomas within the ampulla arise in association with IAPNs.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2004 Mar;11(2):101-5 [15090846.001]
  • [Cites] Arch Pathol Lab Med. 2009 Mar;133(3):423-38 [19260748.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):456-62 [15113850.001]
  • [Cites] Med Sci Monit. 2004 May;10(5):BR139-43 [15114262.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Pancreas. 2004 Aug;29(2):116-22 [15257103.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Dig Dis Sci. 1989 Feb;34(2):167-70 [2536604.001]
  • [Cites] Mod Pathol. 1994 Apr;7(3):376-84 [8058711.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):319-22 [9648163.001]
  • [Cites] Pancreas. 2005 Mar;30(2):115-21 [15714133.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1108-11 [17373748.001]
  • [Cites] J Hepatol. 2007 May;46(5):978-9 [17391800.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Pathology. 2007 Aug;39(4):413-8 [17676483.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):526-8 [17909726.001]
  • [Cites] Abdom Imaging. 2007 Sep-Oct;32(5):644-51 [17437076.001]
  • [Cites] Endoscopy. 2000 May;32(5):389-93 [10817178.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):508-15 [10931449.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):695-702 [11345833.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1510-6 [19440799.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1164-72 [19440145.001]
  • [Cites] J Surg Oncol. 2009 Dec 1;100(7):598-605 [19697352.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):364-70 [20139757.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1304-9 [11743055.001]
  • [Cites] Korean J Radiol. 2002 Jan-Mar;3(1):57-63 [11919480.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Chirurg. 2002 Mar;73(3):235-40 [11963497.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Dig Surg. 2002;19(4):324-7 [12207078.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):328-41 [12353144.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1309-17 [12481012.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):713-23 [12685548.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):571-8 [12717243.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):913-9 [13679455.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):902-10 [14562286.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3329-41 [18651706.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • (PMID = 21084962.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-18; United States / NCI NIH HHS / CA / CA101936
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS315774; NLM/ PMC3168573
  •  go-up   go-down


65. Krishnasamy R, Agarwal S, Singh S, Puri S, Sakhuja P, Agarwal AK: Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case. Hepatobiliary Pancreat Dis Int; 2007 Oct;6(5):553-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case.
  • BACKGROUND: The presence of pancreatic ductal intraepithelial neoplasia in patients with chronic pancreatitis is a risk factor for development of pancreatic adenocarcinoma.
  • METHOD: A case of pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia was diagnosed in the setting of chronic pancreatitis.
  • RESULTS: Distal pancreatectomy combined with splenectomy was performed with a diagnosis of pancreatic body carcinoma.
  • Histopathological examination suggested adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia.
  • The tumor was detected in the remaining head of the pancreas, for which a total pancreatectomy was done.
  • CONCLUSIONS: When a patient with pancreatic ductal intraepithelial neoplasia associated with adenocarcinoma of the pancreas in the setting of chronic pancreatitis is at an increased risk of recurrence in the remaining pancreatic parenchyma, total pancreatectomy may be feasible.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Laparoscopy. Laparotomy / methods. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary. Pancreatectomy / methods. Splenectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):106-7 [18234650.001]
  • (PMID = 17897923.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Albazaz R, Verbeke CS, Rahman SH, McMahon MJ: Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology; 2005;5(4-5):361-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: COX-2 immunostaining was performed on sections of PAC (n = 26), CP (n = 34), PanIN (n = 68) and normal pancreas (n = 11).
  • COX-2 expression was increased in PanIN-2/3 compared to normal pancreas and CP (p < or = 0.001).
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma in Situ / enzymology. Pancreatic Neoplasms / enzymology. Pancreatitis / enzymology. Precancerous Conditions / enzymology. Prostaglandin-Endoperoxide Synthases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / metabolism. Blotting, Western. Cell Count. Chronic Disease. Cyclooxygenase 2. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Membrane Proteins. Middle Aged. Pancreas / anatomy & histology. Pancreas / enzymology. Pancreas / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15980665.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


67. Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, Roth W, Friess H, Schirmacher P: Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol; 2007 Aug;60(8):885-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: cIAP1 might contribute to the regulation of the apoptotic process in the normal and in the neoplastic pancreas, depending on its subcellular localisation.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Adult. Aged. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Cell Line, Tumor. Chronic Disease. Cysts / chemistry. Cytoplasm / chemistry. Cytoplasm / pathology. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry / methods. Male. Middle Aged. Pancreas / chemistry. Pancreas / pathology. Pancreatitis / genetics. Pancreatitis / pathology. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Survival Analysis


68. Layfield LJ, Jarboe EA: Cytopathology of the pancreas: neoplastic and nonneoplastic entities. Ann Diagn Pathol; 2010 Apr;14(2):140-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of the pancreas: neoplastic and nonneoplastic entities.
  • Interpretation of cytologic material obtained from the pancreas is complex because of the large number of reactive processes and benign and malignant neoplasms arising within the pancreas.
  • Whereas separation of neuroendocrine, acinar, and ductal neoplasms is usually straightforward, the greatest diagnostic challenge in pancreatic fine-needle aspiration is the separation of atypical epithelium secondary to chronic pancreatitis from well-differentiated ductal adenocarcinoma.
  • Recently, a number of in situ lesions have been identified, complicating the cytologic diagnosis of pancreatic neoplasia.
  • [MeSH-major] Pancreas / pathology. Pancreatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227021.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


69. Shimamoto T, Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Shimizu A, Uchiyama K, Yokoyama S, Tsutsumi M, Yamaue H: MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas; 2010 Aug;39(6):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the MUC1/glyceraldehyde-3-phosphate dehydrogenase mRNA ratio in carcinoma in situ and minimum invasive IPMC (median, 26,490) was significantly higher than that in IPMA (P = 0.0152).
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Papillary / genetics. Mucin-1 / genetics. Pancreatic Juice / metabolism. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357691.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


70. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol; 2007 Jun;20(6):656-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
  • Here we sought to determine if the proinvasive integrin alpha6beta4 may be related to pancreatic adenocarcinoma tumor progression.
  • Expression of integrin alpha6beta4 was analyzed via immunohistochemistry for the beta4 subunit in normal pancreas, pancreatic intraepithelial neoplasia (PanIN) lesions, pancreatic adenocarcinomas and chronic pancreatitis.
  • In contrast, 93% (13/14) of chronic pancreatitis samples resembled the staining pattern of normal pancreas.
  • We conclude that integrin alpha6beta4 is expressed only on the basal surface of ductal cells in normal pancreas and chronic pancreatitis.
  • During pancreatic adenocarcinoma progression, the alpha6beta4 integrin is dramatically overexpressed and displays altered localization at the earliest stages of PanIN, thus representing an early event in pancreatic adenocarcinoma progression.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415382.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
  • [Other-IDs] NLM/ NIHMS517144; NLM/ PMC4697742
  •  go-up   go-down


71. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, Ouellette MM: Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology; 2007 Oct;51(4):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
  • The aim of this study was to examine TUBB3 expression in pancreatic cancer cell lines, invasive pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • TUBB3 was undetectable in non-neoplastic ducts of the pancreas.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma in Situ / metabolism. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Pancreatic Neoplasms / metabolism. Tubulin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714470.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / TUBB3 protein, human; 0 / Tubulin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


72. Klöppell G, Kosmahl M, Sipos B: Intraductal papillary-mucinous neoplasms: a new and evolving entity among the pancreatic tumors. Verh Dtsch Ges Pathol; 2007;91:66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intraductal papillary-mucinous neoplasms of the pancreas have only recently been recognized as a clinical and pathological entity.
  • They show an adenoma-carcinoma sequence, but have a much more favorable prognosis than ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Carcinoma in Situ / pathology. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314597.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 44
  •  go-up   go-down


73. Shen SG, Zhang D, Hu HT, Li JH, Wang Z, Ma QY: Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol; 2008 Apr 21;14(15):2358-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We cultured the human ductal pancreatic adenocarcinoma cell lines PC-2 and PC-3 and analyzed the mRNA expression of alpha1- and alpha2-adrenergic receptors by reverse transcription polymerase chain reaction (RT-PCR).
  • [MeSH-minor] Adrenergic alpha-1 Receptor Antagonists. Cell Line, Tumor. DNA Replication / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Nick-End Labeling. Piperazines / pharmacology. RNA, Messenger / metabolism. Receptors, Adrenergic, alpha-1 / metabolism. Receptors, Adrenergic, alpha-2 / genetics. Receptors, Adrenergic, alpha-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):50-61 [16292538.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Sep;4(9):526-35 [17728711.001]
  • [Cites] Pancreatology. 2007;7(5-6):459-69 [17912010.001]
  • [Cites] Circulation. 2000 Feb 15;101(6):689-94 [10673263.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4550-5 [10969806.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Pharmacol Res. 2001 Sep;44(3):195-208 [11529686.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):482-9 [11819814.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Herz. 2002 Nov;27(7):683-90 [12439640.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1489-94 [12732361.001]
  • [Cites] Vet Res Commun. 2003 Sep;27 Suppl 1:415-8 [14535443.001]
  • [Cites] Am J Cardiol. 1987 May 29;59(14):18G-28G [2884849.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22235-8 [8226727.001]
  • [Cites] Pharmacol Res. 1996 Apr-May;33(4-5):255-60 [8938018.001]
  • [Cites] J Auton Pharmacol. 1997 Dec;17(6):331-43 [9610428.001]
  • [Cites] Eur J Pharmacol. 1998 Nov 13;361(1):1-15 [9851536.001]
  • [Cites] Eur Urol. 1999;36 Suppl 1:80-8 [10393479.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(1):41-9 [10472778.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41 [16725343.001]
  • (PMID = 18416462.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-2 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Piperazines; 0 / RNA, Messenger; 0 / Receptors, Adrenergic, alpha-1; 0 / Receptors, Adrenergic, alpha-2; 2Y49VWD90Q / Yohimbine; A78GF17HJS / urapidil
  • [Other-IDs] NLM/ PMC2705090
  •  go-up   go-down


74. A-Cienfuegos J, Rotellar F, Martí-Cruchaga P, Valentí V, Zozaya G, Bueno A, Pedano N, Lozano MD, Sola JJ, Pardo F: Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Rev Esp Enferm Dig; 2010 May;102(5):314-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results.
  • Several atypia (IPMN carcinoma in situ) was observed in 2 patients and invasive carcinoma with negative lymph nodes was identified in 3 patients.
  • A patient without invasive carcinoma died at 66 months of follow-up for pancreas adenocarcinoma.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Pancreaticoduodenectomy. Postoperative Period. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524759.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Salvia R, Partelli S, Crippa S, Landoni L, Capelli P, Manfredi R, Bassi C, Pederzoli P: Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg; 2009 Nov;198(5):709-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts.
  • PATIENTS AND METHODS: Our database of patients affected by IPMN was queried to identify patients with a clinicoradiologic or a pathologic diagnosis of multifocal BD-IPMN between January 1990 and December 2006.
  • RESULTS: One hundred thirty-one patients (52 male and 79 female; median age 67 years) had a clinicoradiologic or a histopathologic diagnosis of multifocal BD-IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Humans. Male. Middle Aged. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887201.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Baiocchi GL, Portolani N, Missale G, Baronchelli C, Gheza F, Cantù M, Grazioli L, Giulini SM: Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications. World J Surg Oncol; 2010;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications.
  • Total pancreatectomy was performed in 46% of the cases; in situ and invasive carcinoma were recognized in 15.4% and 38.4% of the cases, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatectomy. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):701-7 [12397279.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Endoscopy. 2006 Jun;38 Suppl 1:S40-7 [16802222.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):304-7 [17693271.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 20374620.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2858722
  •  go-up   go-down


77. Wada K, Kozarek RA, Traverso LW: Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg; 2005 May;189(5):632-6; discussion 637
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
  • Survival was compared between 3 groups: noninvasive IPMN (n = 75), invasive IPMN (n = 25), and invasive ductal adenocarcinoma (n = 24), the latter matched by tumor-node-metastasis (TNM) stage to the IPMN invasive group.
  • Survival curves were not different (P = .11) between the cases matched by stage for those with invasive IPMN cases versus cases with ductal adenocarcinoma.
  • CONCLUSION: Patients with the invasive form of IPMN will have a similarly poor survival as those with ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / surgery
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862510.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Sanada Y, Yoshida K, Ohara M, Tsutani Y: Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res; 2007;13(2):105-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of pancreatic intraepithelial neoplasia (PanIN) were counted, and histologic subtypes of invasive ductal carcinoma of the pancreas (IDC) were determined.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma in Situ / enzymology. Carcinoma, Hepatocellular / enzymology. Gallbladder Neoplasms / enzymology. Liver Neoplasms / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Gallbladder / enzymology. Gallbladder / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Liver / enzymology. Liver / pathology. Male. Middle Aged. Pancreas / enzymology. Pancreas / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2006;6(5):429-39 [16847380.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):987-92 [16142362.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Nov;32(12):1929-34 [16282729.001]
  • [Cites] Pancreas. 2004 Apr;28(3):257-62 [15084967.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):607-15 [16880781.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):245-9 [16012756.001]
  • [Cites] Eur J Cancer. 2003 May;39(7):975-80 [12706367.001]
  • [Cites] Pancreas. 2006 Mar;32(2):164-70 [16552336.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):45-50 [16788943.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):723-31 [14770427.001]
  • [Cites] Pancreas. 2005 Apr;30(3):223-6 [15782098.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):230-6 [1309358.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1223-30 [16211289.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):492-8 [16734727.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):39-62 [15757804.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):621-8 [15105650.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):345-51 [15993511.001]
  • (PMID = 17607371.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


79. Albores-Saavedra J, Wu J, Crook T, Amirkhan RH, Jones L, Hruban RH: Intestinal and oncocytic variants of pancreatic intraepithelial neoplasia. A morphological and immunohistochemical study. Ann Diagn Pathol; 2005 Apr;9(2):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first variant with an intestinal phenotype was associated with mucinous carcinomas that occurred in the tail of the pancreas of 2 men (60 and 65 years old).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / pathology. Intestines / pathology. Oxyphil Cells / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806512.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


80. Carter RR, Woodall CE 3rd, McNally ME, Talboy GE, Lankachandra KM, Van Way CW 3rd: Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors. Am Surg; 2008 Apr;74(4):338-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors.
  • This report is a case of a 58-year-old woman with a mixed ductal-endocrine carcinoma of the pancreas and a synchronous carcinoma-in-situ of the common bile duct.
  • Biopsies from this lesion showed adenocarcinoma.
  • Subsequently, pancreatoduodenectomy was performed for the diagnosis of peri-ampullary carcinoma.
  • Gross examination revealed a 2-cm irregular, ulcerated lesion obstructing the distal 0.5 cm of the common bile duct within the head of the pancreas.
  • On histopathological examination, it was discovered that this lesion contained two separate neoplasms: papillary carcinoma-in-situ of the intraparenchymal portion of the common bile duct and a mixed ductal-endocrine carcinoma of the pancreas.
  • Mixed ductal-endocrine carcinoma of the pancreas is very rare.
  • Finding it in conjunction with a synchronous, overlying papillary carcinoma carcinoma-in-situ of the common bile duct has not been previously described.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Common Bile Duct Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology


81. Esposito I, Seiler C, Bergmann F, Kleeff J, Friess H, Schirmacher P: Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas; 2007 Oct;35(3):212-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Based mainly on animal models, 2 lesions have been suggested as possible precursors of pancreatic ductal adenocarcinoma (PDAC): pancreatic intraepithelial neoplasia (PanIN) and tubular complexes (TCs).
  • [MeSH-minor] Animals. Carcinoma in Situ / pathology. Cell Differentiation. Cell Transformation, Neoplastic. Cystadenoma, Serous / pathology. Disease Progression. Humans. Mice. Mice, Transgenic. Models, Animal. Models, Biological. Pancreatitis, Chronic / pathology. Rats. Species Specificity


82. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol; 2005 Sep;18(9):1193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DeltaNp63 expression in pancreas and pancreatic neoplasia.
  • It is not known whether this marker may have any application in another exocrine organ, the pancreas.
  • A total of 25 cases were non-neoplastic pancreata, 25 were pancreatic intraepithelial neoplasia (PanIN) of various grades, and 50 were examples of pancreatic ductal adenocarcinoma.
  • In conclusion, (I) DNp63 is a reliable marker of squamous differentiation in the pancreas.
  • Among invasive carcinomas, it seems to be entirely specific for areas of squamous differentiation. (II) Those incidental microcysts seen in acinar lobules and lined by attenuated cells are also positive for DNp63, which suggests that they may be metaplastic in nature, and that they do not represent neoplastic cells. (III) Unlike the ducts of other exocrine organs, breast and prostate, there are no DNp63-expressing cells in the normal pancreatic ducts, and therefore, this marker cannot be used in distinguishing invasive carcinomas from the non-invasive ducts. (IV) No p63-expressing 'stem' cells are present in the pancreas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Phosphoproteins / biosynthesis. Trans-Activators / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976814.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / PAR-02-068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


83. Kim JC, Kim MH, Lee TY, Kim JY, Han JH, Park SJ, Lee SS, Seo DW, Jang SJ, Lee SK: [Clinicopathologic review of 41 cases of pancreatic mucinous cystic neoplasms]. Korean J Gastroenterol; 2008 Jan;51(1):34-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were to define the natural history of resected mucinous cystic neoplasms of the pancreas and to identify the findings which suggest malignancy.
  • Thirty three patients (80.6%) had adenoma, 1 (2.4%) borderline malignancy, 1 (2.4%) carcinoma in situ, and 6 (14.6%) invasive mucinous cystadenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2008 Jan;51(1):60-3 [18349566.001]
  • (PMID = 18349560.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


84. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH: PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7380-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
  • PURPOSE: The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis.
  • RESULTS: The PAM4-reactive MUC1 epitope was not detected in normal pancreas but was expressed in 87% (48 of 55) of invasive pancreatic adenocarcinomas, including early stage 1 disease: PAM4 labeled 94% (44 of 47) of the earliest PanIN lesions, PanIN-1A and 1B, along with 91% (10 of 11) of PanIN-2, 40% (2 of 5) of PanIN-3, and 86% (31 of 36) of intraductal papillary mucinous neoplasia lesions.
  • A second, unrelated, anti-MUC1 MAb, MA5, showed considerably less sensitivity with early PanIN-1 lesions; only 61% (25 of 41) were positive and the labeling did not differentiate normal pancreas from PanINs.
  • CONCLUSIONS: The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1.
  • Detection of this biomarker using immunohistology, in vitro immunoassays, and in vivo antibody-based imaging may provide new opportunities for the early detection and improved diagnosis of pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Mucin-1 / metabolism. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Aug 15;14(16):5306; author reply 5306-7 [18698052.001]
  • (PMID = 18094420.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096924; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Mucin-1
  •  go-up   go-down


85. Körner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC: Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am J Pathol; 2005 Oct;167(4):959-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
  • Because the receptors for the gut hormone secretin are poorly characterized, we assessed secretin receptor expression in the main secretin target, the human pancreas.
  • Secretin receptors were highly expressed in non-neoplastic ducts and lobuli and also in lower amounts in ductal neoplasias, including ductal adenocarcinoma, intraductal papillary mucinous tumors, and pancreatic intraepithelial neoplasia.
  • Reverse transcriptase-polymerase chain reaction revealed wild-type receptor mRNA in the non-neoplastic pancreas and both wild-type and spliced variant receptor transcripts in ductal adenocarcinomas.
  • This study is the first to describe the precise secretin receptor distribution in human non-neoplastic pancreas and various pancreatic tumors.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. Receptors, G-Protein-Coupled / metabolism. Receptors, Gastrointestinal Hormone / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Alternative Splicing. Animals. Autoradiography. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Humans. Iodine Radioisotopes. Pancreatic Ducts / metabolism. RNA, Messenger / genetics. Rats

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1998 Mar;184(3):234-9 [9614373.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):382-97 [9453500.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1437-44 [9843782.001]
  • [Cites] Endocrine. 1998 Oct;9(2):171-83 [9867251.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):G487-94 [10444464.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3105-12 [10850463.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Dig Dis. 2001;19(1):15-23 [11385247.001]
  • [Cites] J Membr Biol. 2001 Sep 15;183(2):71-84 [11562789.001]
  • [Cites] Genome Biol. 2001;2(12):REVIEWS3013 [11790261.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):500-11 [11832464.001]
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5223-9 [12234988.001]
  • [Cites] Pharmacol Rev. 2003 Mar;55(1):167-94 [12615957.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1649-54 [14530481.001]
  • [Cites] J Gastroenterol. 2003;38(11):1025-35 [14673718.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Oct 30;102(4):1336-41 [6274336.001]
  • [Cites] J Histochem Cytochem. 1982 Sep;30(9):864-73 [6813372.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 1):G710-7 [6204536.001]
  • [Cites] Cell Tissue Res. 1985;242(3):633-9 [2416452.001]
  • [Cites] Peptides. 1987 Jul-Aug;8(4):633-7 [2819833.001]
  • [Cites] Pancreas. 1988;3(5):529-35 [3186683.001]
  • [Cites] Gastroenterology. 1989 Jun;96(6):1439-44 [2565843.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):713-22 [2572194.001]
  • [Cites] Int J Pancreatol. 1989 Sep;5(2):191-201 [2600453.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1666-74 [2186957.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):316-22 [1702423.001]
  • [Cites] EMBO J. 1991 Jul;10(7):1635-41 [1646711.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G805-10 [8238510.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Feb 27;207(3):883-90 [7864894.001]
  • [Cites] Mol Pharmacol. 1995 Mar;47(3):467-73 [7700244.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] Br J Cancer. 1997;75(10):1467-73 [9166939.001]
  • [Cites] Gut. 1998 Apr;42(4):546-50 [9616318.001]
  • (PMID = 16192632.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Gastrointestinal Hormone; 0 / secretin receptor
  • [Other-IDs] NLM/ PMC1603664
  •  go-up   go-down


86. Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A: Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Res; 2006 Jan 15;66(2):1191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon.
  • Here, we characterize the frequency and pattern of FGF-BP1 expression during the malignant progression of pancreas and colorectal carcinoma.
  • For this, we generated monoclonal antibodies that detect FGF-BP1 protein in formalin-fixed, paraffin-embedded tissues and applied in situ hybridization to detect FGF-BP1 mRNA in adjacent tissue sections.
  • Similarly, pancreatitis (n = 17), pancreatic intraepithelial neoplasia (n = 80), and pancreatic adenocarcinoma (n = 67) showed a significant up-regulation of FGF-BP1 compared with normal pancreas (n = 42; all P < 0.0001, relative to normal).
  • We propose that the up-regulation of the secreted FGF-BP1 protein during initiation of pancreas and colon neoplasia could make this protein a possible serum marker indicating the presence of high-risk premalignant lesions.
  • [MeSH-major] Adenocarcinoma / genetics. Carrier Proteins / biosynthesis. Colonic Neoplasms / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Cell Transformation, Neoplastic. Disease Progression. Gene Expression Profiling. Humans. In Situ Hybridization. Intercellular Signaling Peptides and Proteins. Pancreatitis / genetics. Pancreatitis / pathology. Pancrelipase / physiology. RNA, Messenger / biosynthesis. Risk Assessment. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424058.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009686; United States / NCI NIH HHS / CA / R01 CA 71508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 139946-12-6 / FGFBP1 protein, human; 53608-75-6 / Pancrelipase
  •  go-up   go-down


87. Griffin CA, Morsberger L, Hawkins AL, Haddadin M, Patel A, Ried T, Schrock E, Perlman EJ, Jaffee E: Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations. Cytogenet Genome Res; 2007;118(2-4):148-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.
  • Karyotype analysis can provide clues to significant genes involved in the genesis and growth of pancreas cancer.
  • The genome of pancreas cancer is complex, and G-band analysis cannot resolve many of the karyotypic abnormalities seen.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Metaphase. Nucleic Acid Hybridization


88. Vullierme MP, Giraud-Cohen M, Hammel P, Sauvanet A, Couvelard A, O'Toole D, Levy P, Ruszniewski P, Vilgrain V: Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability. Radiology; 2007 Nov;245(2):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability.
  • PURPOSE: To retrospectively evaluate computed tomographic (CT) findings in patients with in situ and invasive malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to evaluate the accuracy for surgical resectability, with surgery and pathologic analysis as the reference standards.
  • CT findings were retrospectively evaluated to determine if a pancreatic malignant IPMN tumor was present; to make this determination, CT criteria were used to differentiate in situ from invasive tumors and signs of unresectability (liver metastasis, vascular CT pattern of encasement, or regional lymph node metastasis).
  • RESULTS: CT revealed a mural nodule in the pancreatic duct wall in 14 patients with in situ carcinoma and one patient with invasive carcinoma (P < .003).
  • CT revealed an infiltrative pancreatic mass in 17 patients with invasive carcinoma and two patients with in situ carcinoma (P < .02).
  • Of the mural nodules, 93% were seen in patients with in situ carcinoma, whereas 90% of infiltrative pancreatic masses were observed in patients with invasive carcinomas.
  • CONCLUSION: CT is helpful in the differentiation of in situ and invasive IPMN.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / surgery. Adult. Aged. Female. Humans. Male. Preoperative Care / methods. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848678.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F: Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem; 2007 Apr;53(4):629-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker.
  • We identified proteins by use of 2-dimensional gel electrophoresis, peptide fingerprint mapping, and immunodepletion and used immunohistochemistry for in situ localization of the proteins found.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Heat-Shock Proteins / analysis. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. Proteome / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303689.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


90. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


91. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. Dig Surg; 2008;25(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 10 patients with intraductal papillary mucinous neoplasms, 3 patients had minimally invasive adenocarcinoma, and 3 had adenocarcinoma in situ.
  • A medial pancreatectomy was converted to a distal pancreatectomy in 1 patient with adenocarcinoma in situ.
  • CONCLUSIONS: A medial pancreatectomy is a safe and effective alternative for the treatment of intraductal papillary mucinous neoplasm, islet cell tumor, or solid pseudopapillary tumor located in the neck or body of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Islet Cell / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292661.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Stelow EB, Adams RB, Moskaluk CA: The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am J Surg Pathol; 2006 Jan;30(1):36-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma is thought to develop through a series of genetic events through its purported precursor lesion, pancreatic intraepithelial neoplasia (PanIN).
  • Little, however, is known regarding the role of possible precursor lesions in the development of other primary neoplasms of the pancreas.
  • All pancreata resected at the University of Virginia from June 1, 1991 to March 1, 2005 for neoplasia not diagnosed as conventional ductal adenocarcinoma were reviewed and classified according to the World Health Organization's classification schema for tumors of the exocrine and endocrine pancreas.
  • Although the high prevalence of PanIN in pancreata concomitantly harboring certain uncommon neoplasms of the pancreas could signify its role as a precursor lesion for those neoplasms, its high prevalence throughout our series may simply be the result of a coincidental, prevalent finding seen in all pancreata, especially with aging.
  • Because of the ubiquitous nature of PanIN, it should not be used histologically to assist in the diagnosis and subclassification of pancreatic neoplasia.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Age Factors. Aged. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330940.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Yamaguchi T, Shirai Y, Ishihara T, Sudo K, Nakagawa A, Ito H, Miyazaki M, Nomura F, Saisho H: Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy. Cancer; 2005 Dec 15;104(12):2830-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
  • BACKGROUND: The examination of pancreatic juice cytology could hypothetically contribute to the establishment of a definite diagnosis of malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN), but to the authors' knowledge, its significance has not been confirmed to date.
  • METHODS: The study subjects were comprised of 103 patients with IPMN who underwent surgical resection of pancreatic tumors (adenoma in 29 patients, borderline in 17 patients, carcinoma in situ in 25 patients, and invasive carcinoma in 32 patients).
  • RESULTS: The cytologic diagnosis was found to be of nondiagnostic value in only one patient with an IPMN, whereas it was of no diagnostic value in 14 of the patients with pancreatic carcinoma (17.3%), a difference that was statically significant (P < 0.001).
  • The location of the IPMN (either in the pancreas or the pancreatic ducts) was not found to significantly affect the diagnostic value of the test.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Juice / cytology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Endoscopy, Digestive System / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reference Values. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16287152.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. De Raffele E, Mirarchi M, Vaccari S, Santini D, Calculli L, Pendino GM, Cola B: [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms]. Chir Ital; 2009 Sep-Dec;61(5-6):667-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms].
  • [Transliterated title] Resezione della coda del pancreas "spleen preserving" ecoguidata per neoplasia intraduttale mucinosa (IPMN) del pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are a distinct entity with malignant potential, which may recur after surgical excision.
  • We report our technique of intraoperative US-guided resection of non-invasive IPMNs located in the tail of the pancreas with spleen and splenic vessel preservation.
  • Following adequate exposure of the distal pancreas, a thorough ultrasonographic examination of the parenchyma is accomplished to define the features of the neoplasia, its relationship with the main pancreatic duct and splenic vessels and to mark the transection line with electrocautery.
  • Patient 2 was a 60-year-old male who underwent intraoperative US-guided resection of the pancreatic tail for an IPMN of the pancreatic tail measuring 30 mm with carcinoma in situ at histology, and was discharged 9 days after surgery.
  • Limited distal pancreatic resection with spleen and splenic vessel preservation is an adequate surgical technique for non-invasive IPMN of the tail of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography. Spleen

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380276.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


95. Kim YN, Park SY, Kim YK, Moon WS: Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ. J Korean Med Sci; 2010 Dec;25(12):1814-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ.
  • Pylorus-preserving pancreaticoduodenectomy was performed and diagnosis of XGP combined with intraductal papillary mucinous carcinoma in situ was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Granuloma / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis. Xanthomatosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Mar;28(3):254-7 [14961199.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):36-8 [15471123.001]
  • [Cites] Med Sci Monit. 2008 Nov;14(11):CS130-3 [18971878.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):704-7 [16120922.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):240-2 [18392724.001]
  • [Cites] Urology. 1994 Mar;43(3):295-9 [8134982.001]
  • (PMID = 21165301.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2995240
  • [Keywords] NOTNLM ; Cystic Tumor / Pancreas / Xanthogranulomatous Inflammation
  •  go-up   go-down


96. Chiang KC, Hsu JT, Chen HY, Jwo SC, Hwang TL, Jan YY, Yeh CN: Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report. World J Gastroenterol; 2009 Feb 7;15(5):628-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report.
  • Cystic neoplasms of the pancreas are relatively rare, comprising 10 percent of pancreatic cysts and only 1 percent of pancreatic cancers.
  • Cystic neoplasms include mucinous cystic neoplasms, serous cystadenomas, papillary cystic tumors, cystic islet cell tumors and intraductal papillary mucinous neoplasms of the pancreas (IPMNs).
  • Here we present a 72-year-old male diagnosed with IPMN (carcinoma in situ) in the pancreatic head and a branch duct type IPMN (duct atypia) in the pancreatic body and tail.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / radiography. Carcinoma in Situ / ultrasonography. Endoscopy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Outcome. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):188-91 [